4-(5-bromopyridin-3-yl)thiomorpholine 1,1-dioxide | 1244059-79-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(5-bromopyridin-3-yl)thiomorpholine 1,1-dioxide
• 英文别名: 4-(5-bromopyridin-3-yl)thiomorpholine-1,1-dioxide；4-(5-Bromopyridin-3-yl)thiomorpholine 1,1-dioxide；4-(5-bromopyridin-3-yl)-1,4-thiazinane 1,1-dioxide
• CAS: 1244059-79-7
• 化学式: C₉H₁₁BrN₂O₂S
• 分子量: 291.169
• InChiKey: VTPFXYSFOUHFHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,5-二溴吡啶 、 硫代吗啉-1,1-二氧化物 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 以35.8%的产率得到4-(5-bromopyridin-3-yl)thiomorpholine 1,1-dioxide
  参考文献：
  名称：

  [EN] HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS
  [FR] COMPOSÉS PYRROLOTRIAZINE AMINE À SUBSTITUTION HÉTÉROARYLE EN TANT QU'INHIBITEURS DE PI3K

  摘要：

  揭示了Formula (I)的化合物；或其盐；其中Qi是(i) C1、Br、I、-CN、-CH3或-CF3；或(ii) 带有R1的嘧啶唑、三唑或吡啶基；Q2是带有R2和R3的吡啶基、吲唑基、异喹啉基或苯并[d]咪唑基；而R1、R2和R3在此有定义。还揭示了将这些化合物用作PI3K调节剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症和自身免疫疾病方面具有用途。

  公开号：

  WO2016064958A1

文献信息

• Pyridine Derivative and Medicinal Agent
  申请人：Fujihara Hidetaka

  公开号：US20130225548A1

  公开（公告）日：2013-08-29

  A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, which may be substituted by an optionally substituted alkyl group, a hydroxy group, a halogen atom or a group represented by general formula [2]. In formula [2], -L 1 -L 2 -L 3 -R A [2] L 1 and L 3 independently represent a single bond, an alkylene group or a cycloalkylene group; L 2 represents a single bond, O, or NR B ; R B represents H or an optionally substituted alkyl group; and R A represents B, an amino group, a cyano group, a hydroxy group, an alkoxy group, an aryl group, a monoalkylamino group, a dialkylamino group, a carbamoyl group, an alkyloxycarbonyl group, a monoalkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkylcarbonylamino group, and a saturated heterocyclic group, among other groups.

  本发明的一个主要对象是提供一种由下述通用式[1]表示的新型吡啶衍生物或其药学上可接受的盐。在式[1]中，R代表芳基或杂芳基，可以被可选择地取代的烷基、羟基、卤原子或通式[2]所代表的基团所取代。在式[2]中，-L1-L2-L3-RA[2]L1和L3独立地代表单键、烷基或环烷基；L2代表单键、O或NRB；RB代表氢或可选择地取代的烷基；RA代表B、氨基、氰基、羟基、烷氧基、芳基、单烷基氨基、双烷基氨基、氨基甲酰基、烷氧羰基、单烷基氨基羰基、双烷基氨基羰基、烷基羰基氨基和饱和杂环基等基团，以及其他基团。
• PYRIDINE DERIVATIVE AND MEDICINE
  申请人：NIPPON SHINYAKU CO., LTD.

  公开号：US20150225404A1

  公开（公告）日：2015-08-13

  The main purpose of the invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include a pyridine derivative represented by general formula [1], and a pharmaceutically acceptable salt thereof. This compound or a pharmaceutically acceptable salt thereof exhibits mGluR5 inhibitory activity, and can therefore be used as an agent for the prevention or treatment of, e.g., pain (for example, acute pain, chronic pain, inflammatory pain, neuropathic pain, hyperalgesia, thermal hyperalgesia, allodynia, pain due to noxious thermal stimulation, pain due to noxious mechanical stimulation, pain in the lower urinary tract or reproductive organs, or migraine), pruritus, lower urinary tract symptoms or lower urinary tract dysfunctions, gastroesophageal reflux disease (GERD), gastroesophageal reflux associated with transient lower esophageal sphincter relaxation (TLESR), and diseases of the central nervous system.

  本发明的主要目的是提供一种新型吡啶衍生物或其药学上可接受的盐。本发明的例子包括由通式[1]表示的吡啶衍生物及其药学上可接受的盐。该化合物或其药学上可接受的盐表现出mGluR5抑制活性，因此可用作预防或治疗疼痛（例如急性疼痛、慢性疼痛、炎症性疼痛、神经病理性疼痛、过敏性疼痛、热性过敏、触觉过敏、因有害热刺激引起的疼痛、因有害机械刺激引起的疼痛、下尿路或生殖器官的疼痛或偏头痛），瘙痒、下尿路症状或下尿路功能障碍、胃食管反流病（GERD）、胃食管反流伴随瞬时下食管括约肌松弛（TLESR）以及中枢神经系统疾病的药剂。
• PYRIDINE DERIVATIVE AND MEDICINAL AGENT
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP2634176A1

  公开（公告）日：2013-09-04

  [Problem to be Solved by the Invention] A main object of the present invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. [Means of Solving the Problems] A pyridine derivative or a pharmaceutically acceptable salt represented by the following genaral formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, wherein each of the aryl group and the heteroaryl group may be substituted by one or two substituents independently selected from the group consisting of an optionally substituted alkyl group, a hydroxy group, a halogen atom and a group represented by general formula [2]. In formula [2],         -L1-L2-L3-RA L1 and L3 independently represent a single bond, an alkylene group or a cycloalkylene group; L2 represents a single bond, O, or NRB; RB represents H or an optionally substituted alkyl group; RA represents H, an amino group, a cyano group, a hydroxy group, an alkoxy group, an aryl group, a monoalkylamino group, a dialkylamino group, a carbamoyl group, an alkyloxycarbonyl group, a monoalkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkylcarbonylamino group, a saturated heterocyclic group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group or an optionally substituted heteroaryl group.

  [本发明要解决的问题］ 本发明的主要目的是提供一种新型吡啶衍生物或其药学上可接受的盐。 [解决问题的方法］ 由下式[1]代表的吡啶衍生物或其药学上可接受的盐。 在式[1]中，R 代表芳基或杂芳基，其中每个芳基和杂芳基可被一个或两个取代基取代，这些取代基独立地选自任选取代的烷基、羟基、卤素原子和通式[2]所代表的基团组成的组。在式 [2] 中 -L1-L2-L3-RA L1 和 L3 各自代表单键、亚烷基或环烷基；L2 代表单键、O 或 NRB；RB 代表 H 或任选取代的烷基；RA 代表 H、氨基、氰基、羟基、烷氧基、芳基、单烷基氨基、二烷基氨基、氨基甲酰基、烷氧基羰基、单烷基氨基羰基、二烷基氨基羰基、烷基羰基氨基、饱和杂环基、任选取代的烷基、任选取代的环烷基或任选取代的杂芳基。
• Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10023576B2

  公开（公告）日：2018-07-17

  Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

  公开了式(I)化合物；或其盐；其中Qi是(i)Cl、Br、I、-CN、-CH3或-CF3；或(ii)吡唑、三唑或吡啶基，各自被R1取代；Q2是吡啶基、吲唑基、异喹啉基或被R2和R3取代的苯并[d]咪唑基；R1、R2和R3在本文中定义。还公开了使用此类化合物作为 PI3K 调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓炎症性和自身免疫性疾病。
• EP2891656
  申请人：——

  公开号：——

  公开（公告）日：——